IOVANCE BIOTHERAPEUTICS, INC. — Director's Dealing 2021

Jan 6, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK: 0001425205
Period of Report: 2021-01-04

Reporting Person: Fardis Maria (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-04	Stock Option (right to buy)	$46.26	A	250000	Acquired	2031-01-04	Common Stock (250000)	Direct

Footnotes

F1: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.